Remacemide hydrochloride_product_DataBase

Bioactivity	Remacemide hydrochloride (FPL 12924AA), a moderate inhibitor of the Na+ channel, is a weak uncompetitive NMDA receptor antagonist with IC50s of 68 μM and 76 μM for MK-801 binding and NMDA currents, respectively[1]. Remacemide hydrochloride is an anticonvulsant agent[2].
Target	IC50: 68-76 μM (NMDA receptor)IC50:160.6 μM(sodium channel)
Invitro	Remacemide (hydrochloride) (0-1000 μM) blocks voltage-gated Na+ channels in rat cortical synaptosomes in a concentration-dependent manner,with an IC50 value of 160.6 μM[2].
In Vivo	Treatment with low- and high-dose Remacemide (100 mg/kg and 150 mg/kg) delays the acquisition of audio/visual discrimination (AVD) task performance in female Sprague-Dawley rats[3]. Animal Model:
Name	Remacemide hydrochloride
CAS	111686-79-4
Formula	C17H21ClN2O
Molar Mass	304.81
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. G C Palmer, et al. Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Ann N Y Acad Sci. 1995 Sep 15;765:236-47; discussion 248. [2]. Sarah Santangeli, et al. Na+ channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. Eur J Pharmacol. 2002 Mar 1;438(1-2):63-8. [3]. L K M Wright, et al. Behavioral effects associated with chronic ketamine or remacemide exposure in rats. Neurotoxicol Teratol. May-Jun 2007;29(3):348-59.

PeptideDB